World's Best Scientists 2026 revealed!
Award Badge
Best Scientists
2025
Award Badge
Medicine
UK
2026

D-Index & Metrics

Best Scientists

D-Index
169
Citations
142184
World Ranking
894
National Ranking
93

Medicine

D-Index
172
Citations
151257
World Ranking
484
National Ranking
58

Research.com Recognitions

  • 2026 - Research.com Medicine in United Kingdom Leader Award
  • 2025 - Research.com Best Scientists Award
  • 2025 - Research.com Medicine in United Kingdom Leader Award
  • 2023 - Research.com Medicine in United Kingdom Leader Award

Overview

David Cunningham is affiliated with the Royal Marsden NHS Foundation Trust in the United Kingdom. Their research primarily focuses on the field of Medicine, with a significant concentration on Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, Surgery, and Cancer Research.

The main topics of David Cunningham's work include:

  • Lymphoma Diagnosis and Treatment
  • Gastric Cancer Management and Outcomes
  • Colorectal Cancer Treatments and Studies
  • Esophageal Cancer Research and Treatment
  • CAR-T cell therapy research
  • Pancreatic and Hepatic Oncology Research
  • Cancer Genomics and Diagnostics

Recent notable papers authored or co-authored by Cunningham include:

  • "Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial" (2022, Journal of Clinical Oncology)
  • "International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI" (2020, Blood)
  • "Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study" (2021, The Lancet)
  • "Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial" (2022, The Lancet. Gastroenterology & Hepatology)
  • "Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C" (2023, New England Journal of Medicine)

Frequent co-authors collaborating with Cunningham include:

  • Ian Chau (72 co-authorships)
  • Naureen Starling (59 co-authorships)
  • Ruwaida Begum (32 co-authorships)
  • Sheela Rao (27 co-authorships)
  • Bhupinder Sharma (27 co-authorships)

Cunningham has published extensively in various scientific journals. Venues with significant numbers of publications include:

  • Journal of Clinical Oncology (30 publications)
  • Annals of Oncology (19 publications)
  • Blood (14 publications)
  • British Journal of Haematology (11 publications)
  • European Journal of Cancer (7 publications)

In addition to journal articles, Cunningham has contributed to book publications, including one titled Ruling by Other Means released in 2020 by Cambridge University Press, which has been cited in subsequent research.

Best Publications

  • Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer

    David Cunningham;William H. Allum;Sally P. Stenning;Jeremy N. Thompson

  • Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

    David Cunningham;Yves Humblet;Salvatore Siena;David Khayat

  • Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

    Juan Ignacio Valle;Harpreet Singh Wasan;Daniel H Palmer;David Cunningham

  • Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

    J Y Douillard;D Cunningham;Arnaud Roth;M Navarro

  • Capecitabine and oxaliplatin for advanced esophagogastric cancer.

    David Cunningham;Alicia F C Okines;Sue Ashley

  • Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

    Hansjochen Wilke;Kei Muro;Eric Van Cutsem;Sang Cheul Oh

  • Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

    Jean Yves Douillard;Kelly S. Oliner;Salvatore Siena;Josep Tabernero

  • Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

    John P. Neoptolemos;John P. Neoptolemos;Daniel H. Palmer;Daniel H. Palmer;Paula Ghaneh;Eftychia E. Psarelli

  • The role of probiotics in aquaculture

    José Luis Balcázar;Ignacio de Blas;Imanol Ruiz-Zarzuela;David Cunningham

  • Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

    Eric Van Cutsem;Claus Henning Köhne;István Láng;Gunnar Folprecht

  • Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

    Jean Yves Douillard;Salvatore Siena;James Cassidy;Josep Tabernero

  • Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

    David Cunningham;Seppo Pyrhönen;Roger D James;Cornelis J A Punt

  • Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial

    John P. Neoptolemos;Deborah D. Stocken;Claudio Bassi;Paula Ghaneh

  • Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

    Georgios Vlachogiannis;Somaieh Hedayat;Alexandra Vatsiou;Yann Jamin

  • Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    A. Okines;M. Verheij;W. Allum;D. Cunningham

  • Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

    Andrea Wang-Gillam;Chung-Pin Li;György Bodoky;Andrew Dean

  • CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

    Robert Marcus;Kevin Imrie;Andrew Belch;David Cunningham

  • Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin

    S J Arnott;D Cunningham;J Gallagher;R Gray

  • Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

    A Webb;D Cunningham;J H Scarffe;P Harper

  • European evidence-based guidelines on pancreatic cystic neoplasms

    Marco Del Chiaro;Marc G. Besselink;Lianne Scholten;Marco J. Bruno

Frequent Co-Authors

Ian Chau
Ian Chau Royal Marsden NHS Foundation Trust
A. R. Norman
A. R. Norman Royal Marsden NHS Foundation Trust
Andrew Wotherspoon
Andrew Wotherspoon Royal Marsden NHS Foundation Trust
Gina Brown
Gina Brown Imperial College London
Juan W. Valle
Juan W. Valle University of Manchester
Josep Tabernero
Josep Tabernero Vall d´Hebron Institute of Oncology
Bengt Glimelius
Bengt Glimelius Uppsala University
John Radford
John Radford University of Manchester
David C. Linch
David C. Linch University College London
John P. Neoptolemos
John P. Neoptolemos Heidelberg University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The journey to a medical career in the USA is diverse, with multiple educational avenues available online. If you are looking for a patient-facing career without a long admissions process, consider exploring the easiest nursing schools to get into. These programs often offer flexible admissions and support for aspiring nurses at all stages.

Some online ABSN programs let you skip common standardized tests, such as the TEAS or HESI. If you’re seeking an alternative pathway, browse absn programs that don't require teas to find accessible options.

Beyond clinical roles, administrative and support positions are also in demand. Those interested in healthcare administration may benefit from pursuing the best online healthcare administration degree for leadership and management roles. Alternatively, if you prefer office-based work, you can explore reputable medical billing and coding online schools that accept financial aid.

Whether you’re aiming for direct patient care or a specialized administrative path, these educational options make it easier to pursue a healthcare career that fits your goals.

Best Scientists Citing David Cunningham

Trending Scientists

Recently Published Articles